MRD detection for ovarian cancer with low CA125
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This study looks at whether a blood test (MRD) can predict how well treatment works for ovarian cancer patients who do not have high CA125 levels, helping doctors choose better therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- You have ovarian cancer confirmed by a biopsy
- Your CA125 level was 200 or lower when first diagnosed or when cancer came back
- You are in good enough health to walk around and take care of yourself (PS score 0-2)
- You have enough tumor tissue from a previous surgery or biopsy for genetic testing
- You are willing to join and sign a consent form
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well a blood test called CA-125, along with other markers and checkups, can detect ovarian cancer early. It’s for women considered low risk who will do regular blood tests and possibly a vaginal ultrasound if results suggest it.
This trial tests a new blood-based test (OCS) that looks for tiny particles from tumor cells to watch for cancer returning after initial treatment. It is for women with ovarian cancer whose CA125 levels were normal before starting treatment.
This study is for women with advanced ovarian cancer who have finished first treatment and are in complete remission. It uses a blood test to look for tiny amounts of leftover cancer cells, which could help guide future care.
This trial is testing a special blood test (called personalized ctDNA MRD) to see if it can give early warning about cancer returning after treatment. If you have cervical cancer that can be treated with surgery or chemoradiation, and you haven't had treatment yet, you may be eligible.
This trial is looking at how doctors can better use the CA125 blood test to find ovarian cancer earlier. If you are being tested for ovarian cancer in primary care, this study might help improve how future patients are diagnosed.
This study is testing a new way to predict if ovarian cancer will come back after treatment. By looking at tiny particles called exosomes in your blood, researchers hope to create a score that can guide future care.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.